Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches

12 Nov 2009

Abstract excerpt

Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Hepatitis B Virus Studies
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19906917
DOI: 10.1128/jvi.01927-09

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Papillomavirus Prophylactic Vaccines: Established Successes, New ApproachesPMID 19906917Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

Human papillomavirus vaccinesSemantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Developments in L2-based human papillomavirus (HPV) vaccinesSemantic proximity Read ↗

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human CancerSemantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

Diseases caused by human papillomaviruses (HPV)Semantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

[What clinicians should know about human papilloma virus vaccines].Semantic proximity Read ↗

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2Semantic proximity Read ↗

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.